point mutation

Point mutations arise from base substitutions during DNA replication or from mutagen exposure (e.g., UV light causing pyrimidine dimers, deaminating agents, alkylating agents). They are categorized by their effect on protein-coding sequence: (1) Silent mutation - the base change does not alter the amino acid sequence, usually due to redundancy in the genetic code (wobble position), and is typically benign; (2) Missense mutation - the base change results in a different amino acid being incorporated (e.g., sickle cell anemia, where glutamic acid is replaced by valine at position 6 of the beta-globin chain due to a single point mutation); (3) Nonsense mutation - the base change creates a premature stop codon, leading to a truncated, often nonfunctional protein (e.g., some cases of beta-thalassemia, cystic fibrosis). Point mutations can also be classified by the type of substitution: transitions (purine-to-purine or pyrimidine-to-pyrimidine changes, e.g., A to G) are more common and often less deleterious, while transversions (purine-to-pyrimidine or vice versa) are less common. Clinically, point mutations underlie many genetic diseases and are relevant in oncology (e.g., RAS, p53 mutations), hematology (sickle cell disease, thalassemias), and pharmacogenomics. DNA repair mechanisms (mismatch repair, base excision repair) normally correct these errors; defects in repair pathways (e.g., Lynch syndrome due to mismatch repair gene mutations) increase mutation accumulation and cancer risk. Distinguishing point mutations from other mutation types (insertions, deletions, frameshift mutations, trinucleotide repeat expansions) is a key USMLE testing point, as frameshift mutations from insertions/deletions typically have more severe consequences than point mutations.